Collaboration Overview
Absci Corporation has announced a partnership with Memorial Sloan Kettering Cancer Center (MSK) to create new cancer treatments using generative AI. This collaboration aims to develop innovative therapeutics across six different programs. With Absci’s Integrated Drug Creation™ platform, both organizations will work together to leverage their strengths in cancer research and drug development.
Key Details
- Absci is a generative AI drug creation company focused on biologics.
- The collaboration with MSK will enhance research efforts to combat cancer.
- Absci has previously partnered with major pharmaceutical companies like AstraZeneca and Merck.
- The company is also developing its own drug candidates, including a promising anti-TL1A antibody, ABS-101.
Importance of the Partnership
This collaboration is significant as it combines advanced AI technology with MSK’s expertise in oncology. The goal is to accelerate the discovery and development of new therapies for cancer patients. By integrating generative AI with traditional research methods, this partnership could lead to breakthroughs in treatment and improve patient outcomes. As cancer remains a leading cause of death worldwide, innovative approaches such as this are vital in the fight against this devastating disease.
